The cysteinyl (Cys) leukotrienes (LT)C 4 , LTD 4 , and LTE 4 , are lipid mediators that have been implicated in the pathogenesis of asthma. The human LTD 4 receptor (CysLT 1 R) was recently cloned and characterized. The present work was undertaken to study the potential modulation of CysLT 1 R expression by the Th2 cytokines IL-13 and IL-4. In this study, we report that IL-13 up-regulates CysLT 1 R mRNA levels, with consequently enhanced CysLT 1 R protein expression and function in human monocytes and monocyte-derived macrophages. CysLT 1 R mRNA expression was augmented 2-to 5-fold following treatment with IL-13 and was due to enhanced transcriptional activity. The effect was observed after 4 h, was maximal by 8 h, and maintained at 24 h. IL-4, but not IFN-␥, induced a similar pattern of CysLT 1 R up-regulation. Monocytes pretreated with IL-13 or IL-4 for 24 h showed enhanced CysLT 1 R protein expression, as assessed by flow cytometry using a polyclonal anti-CysLT 1 R Ab. They also showed enhanced responsiveness to LTD 4 , but not to LTB 4 , in terms of Ca 2؉ mobilization, as well as augmented chemotactic activity. Our findings suggest a possible mechanism by which IL-13 and IL-4 can modulate CysLT 1 R expression on monocytes and macrophages, and consequently their responsiveness to LTD 4 , and thus contribute to the pathogenesis of asthma and allergic diseases. The Journal of Immunology, 2001, 167: 2855-2860.
L eukotrienes (LTs), 3 which are derived through the 5-lipoxygenase pathway of arachidonic acid metabolism, are lipid mediators of inflammation and immediate hypersensitivity (1-3). The cysteinyl (Cys)LTs, LTC 4 , LTD 4 , and LTE 4 (components of the slow-reacting substance of anaphylaxis), are potent lipid mediators implicated mainly in acute bronchoconstriction and chronic airway inflammation in asthma. When instilled into the airways, they mimic many of the features of human asthma, including bronchoconstriction, mucus secretion, and airway hyperresponsiveness (AHR) (1) (2) (3) (4) . Recently, Lynch et al. (5) and Sarau et al. (6) reported the cloning and characterization of a high affinity cell surface human LTD 4 receptor (CysLT 1 R) that belongs to the G protein-coupled receptor family. In normal lung, CysLT 1 R mRNA was found to be expressed in macrophages as well as in peribronchial smooth muscle (5) .
The inflammatory pathology associated with asthma is thought to be mediated by Th2 lymphocytes and their cytokine network. Numerous studies of bronchoalveolar lavage (BAL) and biopsies from asthmatic airways have shown an increase in CD4 ϩ T lymphocytes producing Th2-like cytokines, IL-4, IL-5, and IL-13 (7) (8) (9) . They have suggested the importance of these cytokines in AHR, which is one of the defining features of asthma and believed to result from chronic inflammation of the bronchial mucosa. Significantly elevated expression of IL-13 mRNA and protein has been observed in BAL cells of patients with atopic asthma after allergen challenge (10) . More recently, blockade of IL-13 before aeroallergen challenge was shown to be sufficient to attenuate AHR (11) . Unlike IL-4, the production of IL-13 can be sustained through the late asthmatic response, and the concentration of secreted IL-13 strongly correlates with the number of eosinophils in BAL and in bronchial submucosa (12) . Together, these results suggest that IL-13 plays an important role in the pathogenesis of asthma.
IL-13 and IL-4 have several overlapping biological activities (13, 14) that may be due to a shared receptor subunit, IL-4R␣ (15) , and signaling through a shared STAT6-dependent pathway (16) . In addition to potent anti-inflammatory properties on macrophages and other cells (17) (18) (19) (20) , both cytokines also induce several immunostimulatory functions, such as increase in VCAM-1 expression on the surface of endothelial cells and induction of monocyte chemoattractant protein-1 (MCP-1) production (21, 22) . Because both LTs and Th2 cytokines are major players in asthma and because the level of expression of CysLT 1 R could be expected to affect cellular responses to LTD 4 , we initiated the present study to investigate the potential for IL-13 and IL-4 to modulate the expression and function of CysLT 1 R.
Materials and Methods

Cells
Monocytes were obtained from peripheral blood of healthy medication-free volunteers, following informed consent in accordance with an Internal Review Board-approved protocol. Peripheral blood leukocytes were enriched by dextran sedimentation, layered over a Ficoll-Hypaque cushion, and centrifuged at 400 ϫ g for 20 min. Mononuclear leukocytes were collected at the interface and washed twice with PBS and resuspended in RPMI 1640 (Life Technologies, Burlington, Ontario, Canada) supplemented with 10% heat-inactivated FBS (Sigma-Aldrich, Oakville, Ontario, Canada), 100 U/ml penicillin, and 100 g/ml streptomycin in a humidified atmosphere with 5% carbon dioxide at 37°C. Monocytes were then purified by adherence (60 min, 37°C) on plastic petri dishes coated with defibrinized autologous serum and removed with EDTA (0.01 M) in RPMI 1640 -10% FBS. Cells were resuspended in RPMI 1640 -10% FBS at 1 ϫ 10 6 cells/ml and allowed to rest overnight before stimulation with the appropriate stimuli.
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Adherent cells cultured on plastic petri dishes for up to 5 days were referred to as monocyte-derived macrophages. 
Cytokines and reagents
Northern blot analysis
Total cellular RNA was extracted by the guanidium thiocyanate method (23) , separated by electrophoresis on 1% agarose, and transferred onto a Hybond-N ϩ (Amersham Pharmacia Biotech, Baie d'Urfé, Quebec, Canada) membrane for Northern analysis. The cDNA corresponding to the whole coding sequence of human CysLT 1 R (5) was amplified by PCR from DNA of human monocytes, using the primers 5Ј-CGGGATCCGATGA AACAGGAAATC-3Ј as sense and 5Ј-CCGGAATTCAATGGGTTTAAA CTATAC-3Ј as antisense. The amplified CysLT 1 R fragment contained 1014 bp. Control hybridizations were performed with the human GAPDH cDNA probe obtained from the American Type Culture Collection (Manassas, VA). The probes were labeled with a multiprime DNA labeling system (Amersham Pharmacia Biotech) using [␣-
32 P]dCTP (sp. act., 3000 Ci/mmol; Amersham Pharmacia Biotech). Membranes were prehybridized for 4 h in a mixture containing 120 mM Tris (pH 7.4), 600 mM NaCl, 8 mM EDTA (pH 8), 0.1% sodium pyrophosphate, 0.2% SDS, and 100 g/ml heparin; hybridization was performed overnight at 60°C in the same mixture in which the concentration of heparin was increased to 625 g/ml and dextran sulfate at 10% was added. The membranes were then washed once at room temperature for 20 min in 2ϫ SSC (1ϫ SSC: 0.15 M NaCl, 0.15 M sodium citrate (pH 7)) and once with 0.1ϫ SSC. The membranes were exposed to Hyperfilm MP (Amersham Pharmacia Biotech) with intensifying screens at Ϫ80°C.
Nuclear run-on transcription assay
Before nuclei isolation, monocytes were stimulated for 3 or 6 h with IL-13 (10 ng/ml). Following stimulation, cells were washed with ice-cold PBS, and pelleted at 250 ϫ g for 5 min. The cell pellet (5 ϫ 10 7 cells) was then resuspended in 1 ml lysis buffer (10 mM Tris-HCl (pH 7.4), 10 mM KCl, 5 mM MgCl 2 , 0.5% Nonidet P-40 (v/v)), incubated for 5 min on ice, and centrifuged at 500 ϫ g for 5 min at 4°C. The supernatant was discarded, and the nuclei were resuspended in 200 l freezing buffer (50 mM TrisHCl, 40% glycerol (v/v), 5 mM MgCl 2 (pH 8), 0.1 mM DTT) and frozen in liquid nitrogen. For the transcription assay, nuclei were thawed on ice and pelleted at 500 ϫ g for 30 s at 4°C, and the supernatant was discarded. Nuclei were then mixed with 100 l reaction buffer containing 100 mM Tris-HCl (pH 7.9), 300 mM (NH 4 ) 2 SO 4 , 4 mM MgCl 2 , 200 mM NaCl, 0.4 mM EDTA, 1 mM DTT, 40% glycerol, 1 mM each of ATP, CTP, and GTP, 1 l RNase inhibitor (40 U/l RNasin; Promega, Madison, WI), and 150 Ci [␣-
32 P]UTP (3000 Ci/mmol; Amersham Pharmacia Biotech) and incubated at 30°C for 30 min. The 32 P-labeled RNA transcripts were then incubated for a further 10 min at 30°C in the presence of 100 U DNase 1 (10 U/l, RNase free; Promega) and 0.5 mM CaCl 2 . This procedure was followed by addition of 1 vol of 2ϫ proteinase K buffer (20 mM Tris-HCl (pH 7.9), 20 mM EDTA, 1% SDS) and 5 l proteinase K (10 mg/ml) and incubation at 42°C for 30 min. The 32 P-labeled RNA transcripts were then isolated with saturated phenol solution and chloroform-isoamyl alcohol (49/1), mixed well, incubated on ice for 15 min, and then centrifuged for 15 min at 500 ϫ g at 4°C. The elongated RNA was then purified on a Sephadex G-25 column. Before ethanol precipitation, 32 P-labeled RNA transcripts were denatured adding NaOH (final concentration of 0.2 M) for 15 min on ice. The solution was neutralized by the addition of HEPES, pH 5.5 (final concentration of 0.28 M). Elongated 32 P-labeled RNA transcripts were then precipitated adding 1 vol of ethanol and 0.1 vol of 3 M sodium acetate and centrifuged 15 min at 500 ϫ g at 4°C. The pellet was resuspended in 500 l hybridization solution (0.75 M NaCl, 50 mM HEPES (pH 7), 2 mM EDTA (pH 8), 50% deionized formamide, 0.5% SDS, 10ϫ Denhardt's, and 0.5 mg/ml salmon sperm DNA). RNA was then denatured at 90°C for 5 min and hybridized at 42°C for 48 h to 5 g denatured DNA immobilized on positively charged nylon transfer membrane (Mandel, Saint-Laurent, Quebec, Canada) in 3 ml hybridization solution. Membranes were then washed four times at 42°C for 15 min in 0.1ϫ SSC, 0.1% SDS and exposed to Hyperfilm MP with intensifying screens at Ϫ80°C for 2 wk. For immobilization of DNA to membranes, 5 g cDNA was denatured with 0.3 M NaOH at room temperature for 30 min, neutralized with ammonium acetate (final concentration of 1.5 M), and spotted onto nylon membrane using a slot blot apparatus.
Flow cytometry
For flow cytometry studies, cells were washed with PBS and fixed with 2% paraformaldehyde for 15 min at room temperature, followed by permeabilization with 0.1% saponin for an additional 15 min at room temperature. Cells were resuspended with PBS-2% BSA and labeled for 30 min at 4°C with anti-CysLT 1 R Ab or with isotype control Ab. Cells were then washed with cold PBS and incubated for 30 min at 4°C with FITC-conjugated goat anti-rabbit IgG. Finally, cells were washed again and resuspended in PBS before single-color immunofluorescence analysis of 5000 cells was performed on a FACScan flow cytometer (BD Biosciences, San Jose, CA).
Intracellular calcium mobilization
For Ca 2ϩ mobilization assays, 5 ϫ 10 6 cells were loaded in HBSS (Life Technologies) containing 350 mg/L NaHCO 3 and 10 mM HEPES (pH 7) with the calcium indicator fura 2-AM (Molecular Probes, Eugene, OR) for 30 min at room temperature. Loaded cells were washed twice, suspended in fresh loading buffer, and added to a constantly stirred cuvette, maintained at 37°C in a SLM/Aminco spectrofluorometer (SLM Instruments, Urbana, IL). The concentration of extracellular Ca 2ϩ was brought to 1.5 mM by addition of a solution of CaCl 2 into the cuvette 10 min before recordings. Maximal cell fluorescence (F max ) was obtained by adding Triton X-100 to a final concentration of 0.5%. Minimal fluorescence (F min ) was determined by subsequent addition of the chelator EGTA in Tris-HCl buffer (100 mM (pH 9)) at 125 mM. Stimuli consisted of LTD 4 , LTB 4 , and PAF.
Chemotaxis assay
Monocytic chemotactic activity was performed with Boyden chambers using a modified Boyden chamber chemotaxis assay. A volume of 200 l cells (6 ϫ 10 5 ) in RPMI 1640, supplemented with 2.5 mg/ml BSA, was added to the upper chamber. The lower chamber contained graded concentrations of LTD 4 or its vehicle. For chemokinesis studies, both chambers contained LTD 4 or its vehicle. The two chambers were separated by a 5-m-pore-size polycarbonate filter (Osmonics, Westborough, MA). After incubation for 2 h at 37°C in 5% CO 2 , the chambers were disassembled and the upper side of the filter was scraped free of cells. Cells on the lower side were removed with 5 mM EDTA, centrifuged, and resuspended in PBS. An aliquot of 100 l was then counted in the FACScan.
Results
The expression of CysLT 1 R in human monocytes was first investigated by Northern blot analysis of total RNA following 8 h of stimulation with graded concentrations of IL-13 ranging from 1 to 20 ng/ml. As shown in Fig. 1A , human monocytes constitutively expressed low levels of CysLT 1 R mRNA, and IL-13 induced a timedependent augmentation of transcript levels. Accumulation was augmented 3-to 5-fold over baseline, and the effect was detectable as soon as 4 h of stimulation, was maximal at 8 h, and was still detectable at 24 h. IL-13 induced a concentration-dependent augmentation in steady state levels of CysLT 1 R mRNA, which plateaued at 10 ng/ml (Fig. 1B) . In parallel experiments, we also examined the effect of the cytokine IL-4 on CysLT 1 R mRNA expression. Fig. 1C illustrates CysLT 1 R mRNA levels in monocytes and monocyte-derived macrophages following 6 h of incubation in the absence or presence of IL-13 (10 ng/ml) or IL-4 (10 ng/ml). Both cytokines induced similar levels of CysLT 1 R mRNA expression in both cell populations. Fig.  1D illustrates the kinetics of up-regulation of CysLT 1 R mRNA expression by IL-4, with a maximal effect at 4 h of incubation. Fig. 1E shows the effect to be concentration dependent, with up-regulation detectable at 0.1 ng/ml IL-4. Moreover, the Th1-type cytokine IFN-␥ was not capable of up-regulating CysLT 1 R.
In a further series of experiments, we evaluated the mechanisms underlying the accumulation of CysLT 1 R mRNA induced by IL-13. The augmentation of CysLT 1 R mRNA accumulation in monocytes following IL-13 treatment could result from augmentation in mRNA stability and/or gene transcription rate. We first examined the former possibility by assessing CysLT 1 R mRNA decay kinetics with medium-and IL-13-treated monocytes using the RNA synthesis inhibitor, actinomycin D (10 g/ml). Monocytes were incubated 4 h in the presence or absence of IL-13 before addition of actinomycin D, and CysLT 1 R mRNA levels were assessed by Northern blot analysis after periods of 0 -180 min. As illustrated in Fig. 2A , CysLT 1 R mRNA t 1/2 was ϳ2.5 h in unstimulated human monocytes. IL-13 treatment did not induce a significant change in CysLT 1 R mRNA t 1/2 , suggesting that the increased accumulation of CysLT 1 R mRNA by IL-13 was not caused by stabilization of the transcripts. To assess whether IL-13 induced CysLT 1 R mRNA accumulation through a transcriptional mechanism, we performed experiments in which monocytes were pretreated with actinomycin D for 15 min to block new RNA synthesis and were then treated with either medium or IL-13. As shown in Fig. 2B , this pretreatment completely abolished the IL-13-induced accumulation of CysLT 1 R mRNA, suggesting a transcriptional mechanism in the regulation of CysLT 1 R expression by IL-13. Transcriptional activation of the CysLT 1 R gene was confirmed by a nuclear run-on experiment (Fig. 2C ) that showed that nuclear transcription of the CysLT 1 R gene was indeed increased (4-fold at 3 h) by IL-13 treatment.
The next series of experiments examined whether transcription of CysLT 1 R mRNA was associated with an augmented cellular expression of CysLT 1 R protein. Changes in monocyte mRNA levels were paralleled by an increase in cellular expression of CysLT 1 R, as assessed by flow cytometry using specific anti-CysLT 1 R Ab. As illustrated in Fig. 3A , both IL-13 and IL-4 induced a markedly augmented expression of CysLT 1 R protein in monocytes. The effect was maximal following a 24-h stimulation with the cytokines. The effects of the two cytokines were both concentration and time dependent, being maximal at 10 ng/ml after 24 h (Fig. 3, B and C) . Similarly to monocytes, IL-13 and IL-4 also up-regulated the expression of CysLT 1 R in monocyte-derived macrophages (Fig. 3A) .
We finally investigated whether the IL-13-and IL-4-induced upregulation of CysLT 1 R expression was associated with augmented functional responsiveness to LTD 4 . Receptor function was evaluated by mobilization of intracellular calcium upon stimulation with LTD 4 . As illustrated in Fig. 4A , monocytes cultured for 24 h with 10 ng/ml IL-13 or IL-4 showed increased calcium flux in response to LTD 4 Fig. 4B , responsiveness to LTD 4 in monocyte-derived macrophages was augmented even more than in monocytes, following a 24-h incubation with the cytokines IL-13 or IL-4 (10 ng/ml).
The functional relevance of increased CysLT 1 R expression on IL-13-stimulated monocytes was also investigated in terms of modulation of their chemotactic response to LTD 4 . Whereas resting monocytes showed a weak chemotactic response to LTD 4 , Fig. 5A shows that a significantly augmented response to LTD 4 was observed when monocytes had been exposed for 24 h to IL-13. Enhanced migration to LTD 4 was concentration dependent, with activity already present at 1 nM and reaching a plateau between 10 and 100 nM LTD 4 . Similar results were obtained with IL-4-treated cells. Chemokinesis was not affected, however, by pretreatment of cells with either IL-4 or IL-13 (Fig. 5B) . Moreover, monocyte chemotactic responses to the chemokine MCP-1 were not affected by such pretreatment (Fig. 5B ). These observations suggest that the augmentation of CysLT 1 R expression following stimulation with IL-13 or IL-4 is accompanied by an enhanced functional activity of the receptor.
Discussion
The CysLTs, particularly LTD 4 and LTC 4 , are lipid mediators that have been implicated in the pathogenesis of several inflammatory processes, including asthma. Their multiple and diverse cellular actions make them also potential protagonists in a number of other pathological states, such as adult respiratory distress syndrome and pulmonary hypertension. The present work was initiated to study the mechanisms by which the receptor for LTD 4 can be regulated. Our understanding of the mechanisms governing the regulation of CysLT 1 R expression is a prerequisite for attempting to modulate and control CysLT 1 R FIGURE 1. Up-regulation of CysLT 1 receptor gene expression by IL-13 and IL-4 in human monocytes and monocyte-derived macrophages. Northern blot analysis of CysLT 1 R mRNA expression. A, Human monocytes were incubated in the absence (M) or presence of IL-13 (10 ng/ml) for different times, as indicated. B, Monocytes were incubated for 6 h with graded concentrations of IL-13. C, Monocytes or monocyte-derived macrophages were incubated for 6 h with IL-13 or IL-4 (10 ng/ml). D, Monocytes were incubated for 2-8 h in the absence or presence of 10 ng/ml IL-4. E, Monocytes were incubated for 4 h with graded concentrations of IL-4 or with 400 U/ml IFN-␥. Total RNA was purified from monocytes or monocyte-derived macrophages and used in Northern blot analysis, as described in Materials and Methods. Results are representative of at least three separate experiments. expression in various tissues in LTD 4 -mediated diseases, and particularly asthma. In the present study, we have shown that IL-13 and IL-4, two prototypic Th2 cytokines that share many biological effects, up-regulate the expression of the CysLT 1 R in human monocytes and monocyte-derived macrophages. This up-regulation involves transcriptional activation of the CysLT 1 R gene and is associated with enhanced CysLT 1 R protein expression and augmented responsiveness to the ligand LTD 4 in terms of intracellular calcium mobilization and chemotactic activity. In contrast, the prototypic Th1 cytokine IFN-␥ did not modify CysLT 1 R expression.
The pathology associated with asthma is thought to be mediated by Th2 cells and involves potentially important roles for the cytokines IL-4, IL-13, and IL-5, because both mRNA and protein levels of these cytokines are elevated in allergic patients as compared with normal individuals (7) (8) (9) (10) 24) . A particular association between IL-13 and asthma has also been suggested by several studies. IL-13 was produced by BAL cells of atopic asthma patients after allergen challenge (7), and increased IL-13 mRNA was detected in the bronchial mucosa of asthmatic patients (10). More recently, several studies have demonstrated the central role IL-13 appears to play, at least in experimental asthma, in terms of induction of AHR and mucus hypersecretion (11, 25, 26) . Its preferential role in asthma may be due, in part, to its longer half-life in vivo and its higher levels in asthmatic lung, compared with IL-4, and, in part, to its predominant effect on some features of asthma, such as goblet cell activation (11, 25) .
Of the different mediators that are known to be involved in asthma, LTs are considered to be among the most important because they participate in both the bronchoconstriction and the inflammatory components of the disease. In general, cyclooxygenase metabolites of arachidonate are associated with nonallergic inflammation, whereas 5-lipoxygenase metabolites such as LTB 4 , LTC 4 , and LTD 4 are predominantly involved in allergic inflammation. In this context, it is quite interesting that the allergy-associated cytokines IL-13 and IL-4 tend to suppress cyclooxygenase-2 activity (17, 27), whereas they enhance LTA 4 hydrolase activity, resulting in the increased production of LTB 4 (28) . In other reports, IL-13 was shown to enhance 15-hydroxyeicosatetraenoic acid release in monocytes (19, 29) , to increase cytosolic phospholipase A 2 expression, and to modulate zymosan-stimulated arachidonic acid mobilization (30) .
Excessive production of leukocytes and their subsequent invasion of the airways and other target organs are characteristic features of asthma and allergic diseases. Thus, priming of leukocytes with cytokines such as IL-13 and IL-4, combined with an increase in CysLT production in the airways of asthmatics, may contribute to the influx ] i was determined using the fluorescent dye fura 2-AM. A, Human monocytes were cultured for 24 h in the absence or presence of IL-13 or IL-4 (10 ng/ml), loaded with fura 2-AM, and stimulated with 100 nM LTD 4 or 100 nM LTB 4 , in the absence or presence of the CysLT 1 R antagonist MK571 (1 M). B, Human monocyte-derived macrophages were cultured for 24 h in the absence or presence of IL-13 or IL-4 (10 ng/ml), loaded with fura 2-AM, and stimulated with 100 nM LTD 4 . and activation of leukocytes. In another receptor system, IL-13 and IL-4 were shown to augment the expression of the chemokine receptors CXCR1 and CXCR2 in human monocytes (31) . Hence, our findings, in addition to the latter observations, suggest that, in Th2-dominated responses, IL-13 and IL-4 could participate in the recruitment and activation of mononuclear phagocytes. We have also recently shown that CysLT 1 R expression can be up-regulated by the Th2 cytokine IL-5 in eosinophil-differentiated HL-60 cells (32) .
IL-13 exhibits pleiotropic biological functions on multiple cell types, and it shares one chain of its receptor with IL-4. Whereas Janus kinase (JAK)3 is one of the kinases that transduces signals from the IL-4R (33), the signaling pathway of IL-13 seems to be quite variable depending on the cell type. Tyrosine kinases were recently suggested to play a role in the signaling pathway following binding of IL-13, which was shown to induce JAK3 phosphorylation in primary human NK and T cells (34) . In human colon carcinoma cell lines, IL-13 induced phosphorylation and activation of JAK2 (35) , whereas phosphorylation of tyrosine kinase and JAK2 was induced in human monocytes (29) . However, both IL-13 and IL-4 induce the phophorylation and nuclear translocation of the transcription factor STAT6 (16) . The eventual involvement of these signaling molecules in the observed up-regulation of CysLT 1 R by IL-13 or IL-4 remains to be elucidated. The promoter region of the CysLT 1 R gene is undefined at present, but our findings would predict that it contains STAT6-binding elements.
Monocytes and macrophages are believed to play a pivotal role at sites of inflammation, as they have the potential to activate other cell types through the production of stimulatory cytokines. Our findings provide evidence that the cytokines IL-13 and IL-4 can enhance the expression and function of CysLT 1 R, a receptor for a potent proinflammatory lipid mediator. In the context of a Th2 response, IL-13 and IL-4 may thus play a crucial role in the accumulation and activation of mononuclear cells within the inflammatory lesion.
In conclusion, our observations that Th2 cytokines can up-regulate CysLT 1 R expression suggest a mechanism by which IL-13 and IL-4 can modulate leukocyte function and particularly their responsiveness to LTD 4 , and thus possibly contribute to the pathogenesis of asthma and allergic diseases.
